AU2014380174C1 - Overexpression of N-glycosylation pathway regulators to modulate glycosylation of recombinant proteins - Google Patents

Overexpression of N-glycosylation pathway regulators to modulate glycosylation of recombinant proteins Download PDF

Info

Publication number
AU2014380174C1
AU2014380174C1 AU2014380174A AU2014380174A AU2014380174C1 AU 2014380174 C1 AU2014380174 C1 AU 2014380174C1 AU 2014380174 A AU2014380174 A AU 2014380174A AU 2014380174 A AU2014380174 A AU 2014380174A AU 2014380174 C1 AU2014380174 C1 AU 2014380174C1
Authority
AU
Australia
Prior art keywords
cell
day
culture
cells
protein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2014380174A
Other languages
English (en)
Other versions
AU2014380174B2 (en
AU2014380174A1 (en
Inventor
Shivani Gupta
Sohye Kang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Amgen Inc
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=53757626&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AU2014380174(C1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Amgen Inc filed Critical Amgen Inc
Publication of AU2014380174A1 publication Critical patent/AU2014380174A1/en
Publication of AU2014380174B2 publication Critical patent/AU2014380174B2/en
Priority to AU2018264100A priority Critical patent/AU2018264100C1/en
Priority to AU2020239681A priority patent/AU2020239681C1/en
Application granted granted Critical
Publication of AU2014380174C1 publication Critical patent/AU2014380174C1/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/1048—Glycosyltransferases (2.4)
    • C12N9/1051—Hexosyltransferases (2.4.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/005—Glycopeptides, glycoproteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y204/00—Glycosyltransferases (2.4)
    • C12Y204/01—Hexosyltransferases (2.4.1)
    • C12Y204/01101—Alpha-1,3-mannosyl-glycoprotein 2-beta-N-acetylglucosaminyltransferase (2.4.1.101)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y204/00—Glycosyltransferases (2.4)
    • C12Y204/01—Hexosyltransferases (2.4.1)
    • C12Y204/01143—Alpha-1,6-mannosyl-glycoprotein 2-beta-N-acetylglucosaminyltransferase (2.4.1.143)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y204/00—Glycosyltransferases (2.4)
    • C12Y204/01—Hexosyltransferases (2.4.1)
    • C12Y204/01094—Protein N-acetylglucosaminyltransferase (2.4.1.94)

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Saccharide Compounds (AREA)
AU2014380174A 2014-01-29 2014-12-11 Overexpression of N-glycosylation pathway regulators to modulate glycosylation of recombinant proteins Active AU2014380174C1 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
AU2018264100A AU2018264100C1 (en) 2014-01-29 2018-11-15 Overexpression Of N-Glycosylation Pathway Regulators To Modulate Glycosylation Of Recombinant Proteins
AU2020239681A AU2020239681C1 (en) 2014-01-29 2020-09-23 Overexpression Of N-Glycosylation Pathway Regulators To Modulate Glycosylation Of Recombinant Proteins

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201461933137P 2014-01-29 2014-01-29
US61/933,137 2014-01-29
PCT/US2014/069744 WO2015116315A1 (en) 2014-01-29 2014-12-11 Overexpression of n-glycosylation pathway regulators to modulate glycosylation of recombinant proteins

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2018264100A Division AU2018264100C1 (en) 2014-01-29 2018-11-15 Overexpression Of N-Glycosylation Pathway Regulators To Modulate Glycosylation Of Recombinant Proteins

Publications (3)

Publication Number Publication Date
AU2014380174A1 AU2014380174A1 (en) 2016-08-11
AU2014380174B2 AU2014380174B2 (en) 2018-08-30
AU2014380174C1 true AU2014380174C1 (en) 2025-06-05

Family

ID=53757626

Family Applications (3)

Application Number Title Priority Date Filing Date
AU2014380174A Active AU2014380174C1 (en) 2014-01-29 2014-12-11 Overexpression of N-glycosylation pathway regulators to modulate glycosylation of recombinant proteins
AU2018264100A Active AU2018264100C1 (en) 2014-01-29 2018-11-15 Overexpression Of N-Glycosylation Pathway Regulators To Modulate Glycosylation Of Recombinant Proteins
AU2020239681A Active AU2020239681C1 (en) 2014-01-29 2020-09-23 Overexpression Of N-Glycosylation Pathway Regulators To Modulate Glycosylation Of Recombinant Proteins

Family Applications After (2)

Application Number Title Priority Date Filing Date
AU2018264100A Active AU2018264100C1 (en) 2014-01-29 2018-11-15 Overexpression Of N-Glycosylation Pathway Regulators To Modulate Glycosylation Of Recombinant Proteins
AU2020239681A Active AU2020239681C1 (en) 2014-01-29 2020-09-23 Overexpression Of N-Glycosylation Pathway Regulators To Modulate Glycosylation Of Recombinant Proteins

Country Status (14)

Country Link
US (3) US10227627B2 (enExample)
EP (1) EP3099806A1 (enExample)
JP (3) JP6474420B2 (enExample)
KR (3) KR102519540B1 (enExample)
CN (2) CN113774084B (enExample)
AU (3) AU2014380174C1 (enExample)
BR (1) BR112016017606A2 (enExample)
CA (1) CA2938079C (enExample)
CL (1) CL2016001900A1 (enExample)
EA (2) EA202190244A3 (enExample)
IL (3) IL282517B (enExample)
MX (2) MX377780B (enExample)
SG (1) SG10201912081RA (enExample)
WO (1) WO2015116315A1 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101936049B1 (ko) 2015-10-15 2019-01-08 (주)알테오젠 IgG Fc 도메인을 가지는 융합 단백질의 생산방법
SG11201908328XA (en) * 2017-03-14 2019-10-30 Amgen Inc Control of total afucosylated glycoforms of antibodies produced in cell culture
IL321253A (en) 2018-05-01 2025-08-01 Amgen Inc Antibodies with a modulated glycan profile
CN109576212B (zh) * 2018-12-14 2021-06-22 杭州奕安济世生物药业有限公司 高密度接种培养中种子细胞的培养方法及其应用
CN114096659A (zh) * 2019-06-10 2022-02-25 Cho普拉斯公司 用于基于蛋白质的药物的高水平生产的细胞系
BR112023021867A2 (pt) 2021-04-23 2023-12-19 Amgen Inc Composições de anticorpo anti-tslp e seus usos
AU2022269799A1 (en) * 2021-05-03 2023-09-14 Boehringer Ingelheim International Gmbh Method for producing spesolimab
CN113684322B (zh) * 2021-09-09 2024-01-23 上海药明生物技术有限公司 一种降低抗体类蛋白高聚甘露糖型水平的方法
CN114525252B (zh) * 2022-03-10 2023-12-01 广州源井生物科技有限公司 一种提高mda-mb-231单细胞克隆形成率的单克隆增强培养基与培养方法及其应用
AR130862A1 (es) 2022-10-26 2025-01-29 Amgen Inc Composiciones de anticuerpos anti-tslp y usos de las mismas

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011134643A1 (en) * 2010-04-27 2011-11-03 Lonza Ltd. Improved glycosylation of proteins in host cells

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6936694B1 (en) 1982-05-06 2005-08-30 Intermune, Inc. Manufacture and expression of large structural genes
AU588819B2 (en) 1984-10-29 1989-09-28 Immunex Corporation Cloning of human granulocyte-macrophage colony stimulating factor gene
US5672502A (en) 1985-06-28 1997-09-30 Celltech Therapeutics Limited Animal cell culture
US4968607A (en) 1987-11-25 1990-11-06 Immunex Corporation Interleukin-1 receptors
US5075222A (en) 1988-05-27 1991-12-24 Synergen, Inc. Interleukin-1 inhibitors
WO1990005183A1 (en) 1988-10-31 1990-05-17 Immunex Corporation Interleukin-4 receptors
US5395760A (en) 1989-09-05 1995-03-07 Immunex Corporation DNA encoding tumor necrosis factor-α and -β receptors
ATE194384T1 (de) 1989-09-12 2000-07-15 Hoffmann La Roche Tnf-bindende proteine
US6204363B1 (en) 1989-10-16 2001-03-20 Amgen Inc. Stem cell factor
US5149792A (en) 1989-12-19 1992-09-22 Amgen Inc. Platelet-derived growth factor B chain analogs
US5272064A (en) 1989-12-19 1993-12-21 Amgen Inc. DNA molecules encoding platelet-derived growth factor B chain analogs and method for expression thereof
US5350683A (en) 1990-06-05 1994-09-27 Immunex Corporation DNA encoding type II interleukin-1 receptors
WO1991018982A1 (en) 1990-06-05 1991-12-12 Immunex Corporation Type ii interleukin-1 receptors
GB9014932D0 (en) 1990-07-05 1990-08-22 Celltech Ltd Recombinant dna product and method
WO1994004679A1 (en) 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
JPH05244982A (ja) 1991-12-06 1993-09-24 Sumitomo Chem Co Ltd 擬人化ｂ−ｂ１０
NZ257942A (en) 1992-10-23 1996-04-26 Immunex Corp Preparing a mammalian protein by expression of a fusion protein containing a leucine zipper domain
US5981713A (en) 1994-10-13 1999-11-09 Applied Research Systems Ars Holding N.V. Antibodies to intereleukin-1 antagonists
DE69635480T2 (de) 1995-06-29 2006-08-17 Immunex Corp., Thousand Oaks Apoptosis induzierendes cytokin
US6613544B1 (en) 1995-12-22 2003-09-02 Amgen Inc. Osteoprotegerin
US6096728A (en) 1996-02-09 2000-08-01 Amgen Inc. Composition and method for treating inflammatory diseases
US6271349B1 (en) 1996-12-23 2001-08-07 Immunex Corporation Receptor activator of NF-κB
US6235883B1 (en) 1997-05-05 2001-05-22 Abgenix, Inc. Human monoclonal antibodies to epidermal growth factor receptor
GB9722131D0 (en) 1997-10-20 1997-12-17 Medical Res Council Method
US6337072B1 (en) 1998-04-03 2002-01-08 Hyseq, Inc. Interleukin-1 receptor antagonist and recombinant production thereof
AU1920301A (en) 1999-11-17 2001-05-30 Immunex Corporation Receptor activator of nf-kappa b
US6544424B1 (en) 1999-12-03 2003-04-08 Refined Technology Company Fluid filtration system
GB9928787D0 (en) 1999-12-03 2000-02-02 Medical Res Council Direct screening method
GB0025144D0 (en) 2000-10-13 2000-11-29 Medical Res Council Concatenated nucleic acid sequences
US20040202995A1 (en) 2003-04-09 2004-10-14 Domantis Nucleic acids, proteins, and screening methods
US20050186577A1 (en) * 2004-02-20 2005-08-25 Yixin Wang Breast cancer prognostics
PT1720972E (pt) * 2004-03-05 2014-04-07 Dsm Ip Assets Bv Processo para cultura de células por perfusão contínua e fluxo alternativo tangencial
MX2007003320A (es) 2004-09-24 2007-05-18 Amgen Inc Moleculas fc modificadas.
US8053238B2 (en) 2005-10-31 2011-11-08 Unhwa Corporation Isolated population of plant single cells and method of preparing the same
US20070190057A1 (en) * 2006-01-23 2007-08-16 Jian Wu Methods for modulating mannose content of recombinant proteins
WO2008087259A1 (en) * 2007-01-18 2008-07-24 Suomen Punainen Risti, Veripalvelu Novel carbohydrate profile compositions from human cells and methods for analysis and modification thereof
US20100221823A1 (en) * 2007-06-11 2010-09-02 Amgen Inc. Method for culturing mammalian cells to improve recombinant protein production
TW201028431A (en) * 2008-10-31 2010-08-01 Lonza Ag Novel tools for the production of glycosylated proteins in host cells
CA2757079C (en) * 2009-04-20 2015-05-19 Pfizer Inc. Control of protein glycosylation and compositions and methods relating thereto
US20130196410A1 (en) * 2010-03-05 2013-08-01 Alnylam Pharmaceuticals, Inc Compositions and methods for modifying the glycosylation pattern of a polypeptide
AU2011237442A1 (en) * 2010-04-07 2012-10-18 Momenta Pharmaceuticals, Inc. High mannose glycans
US9133493B2 (en) 2011-04-21 2015-09-15 Amgen Inc. Method for culturing mammalian cells to improve recombinant protein production

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011134643A1 (en) * 2010-04-27 2011-11-03 Lonza Ltd. Improved glycosylation of proteins in host cells

Also Published As

Publication number Publication date
EA037565B1 (ru) 2021-04-14
JP6797950B2 (ja) 2020-12-09
EA202190244A3 (ru) 2021-08-31
IL246914A0 (en) 2016-09-29
AU2018264100B2 (en) 2020-07-23
EP3099806A1 (en) 2016-12-07
IL282517B (en) 2022-07-01
MX377780B (es) 2025-03-11
CN113774084B (zh) 2024-04-16
US10907186B2 (en) 2021-02-02
JP7034236B2 (ja) 2022-03-11
JP6474420B2 (ja) 2019-02-27
AU2020239681A1 (en) 2020-10-15
KR20220086703A (ko) 2022-06-23
AU2018264100A1 (en) 2018-12-06
AU2020239681C1 (en) 2025-06-05
MX2016009911A (es) 2016-10-28
US20200277642A1 (en) 2020-09-03
SG10201912081RA (en) 2020-02-27
BR112016017606A2 (pt) 2017-10-10
CN106170554A (zh) 2016-11-30
AU2014380174B2 (en) 2018-08-30
CA2938079C (en) 2022-10-11
CN106170554B (zh) 2021-08-17
IL270861B (en) 2021-05-31
IL270861A (en) 2020-01-30
KR20160111943A (ko) 2016-09-27
CN113774084A (zh) 2021-12-10
EA201691532A1 (ru) 2017-01-30
KR102519540B1 (ko) 2023-04-10
KR102301034B1 (ko) 2021-09-13
MX2020012356A (es) 2021-01-29
IL246914B (en) 2019-12-31
AU2014380174A1 (en) 2016-08-11
US20190153496A1 (en) 2019-05-23
US10655156B2 (en) 2020-05-19
AU2020239681B2 (en) 2022-06-23
IL282517A (en) 2021-06-30
WO2015116315A1 (en) 2015-08-06
JP2019088305A (ja) 2019-06-13
EA202190244A2 (ru) 2021-05-31
KR20210114549A (ko) 2021-09-23
KR102410393B1 (ko) 2022-06-16
US10227627B2 (en) 2019-03-12
JP2022068365A (ja) 2022-05-09
US20190010532A1 (en) 2019-01-10
AU2018264100C1 (en) 2025-06-05
JP2021040638A (ja) 2021-03-18
JP2017505620A (ja) 2017-02-23
CL2016001900A1 (es) 2017-05-12
CA2938079A1 (en) 2015-08-06

Similar Documents

Publication Publication Date Title
AU2020239681C1 (en) Overexpression Of N-Glycosylation Pathway Regulators To Modulate Glycosylation Of Recombinant Proteins
AU2018201844C1 (en) Use Of Monensin To Regulate Glycosylation Of Recombinant Proteins
US10106829B2 (en) Overexpression of N-glycosylation pathway regulators to modulate glycosylation of recombinant proteins
JP7788307B2 (ja) 組換えタンパク質のグリコシル化を調節するためのｎ－グリコシル化経路制御因子の過剰発現
HK1231928B (zh) 过表达n-糖基化途径调节基因以调节重组蛋白的糖基化
EA047078B1 (ru) Сверхэкспрессия регуляторов пути n-гликозилирования для модуляции гликозилирования рекомбинантных белков
HK1231928A1 (en) Overexpression of n-glycosylation pathway regulators to modulate glycosylation of recombinant proteins

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
DA2 Applications for amendment section 104

Free format text: THE NATURE OF THE AMENDMENT IS AS SHOWN IN THE STATEMENT(S) FILED 11 FEB 2025

DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS AS SHOWN IN THE STATEMENT FILED 11 FEB 2025